LAS VEGAS, NV—When used in combination with the calcium channel alpha 2-delta ligands pregabalin and gabapentin, lidocaine 5% patch is well tolerated and safe for postherpetic neuralgia (PHN), ...

opioids In a meta-analysis, researchers evaluated whether a lidocaine patch is beneficial for postoperative pain as an option for multimodal analgesia. The use of lidocaine patches for postoperative ...

The results of this exploratory study suggest that Lidoderm can alleviate the pain associated with OA of the knee. "The results of this exploratory study suggest that Lidoderm can alleviate the pain ...

Specialty pain meds maker Scilex Pharmaceuticals plans to wrap up clinical trials for its lead product, Ztildo – and has just raised $5 million from private investors to do so, according to regulatory ...

The pharmacokinetics, safety, and tolerability of four topical lidocaine patches 5% continuously applied for 72 hours and changed every 12 or 24 hours were examined. In this randomized, prospective, ...

LAS VEGAS, NV—Lidocaine patch 5% is effective and well-tolerated if applied to the face, trunk, or extremities, according to the results of a study in patients with postherpetic neuralgia reported ...

Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm ®. Mylan received final approval from the U.S. Food ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from ...

Please comment on the use of lidocaine patches for back pain. —Felix N. Chien, DO, Rowland Heights, Calif. At this point, there are no large, randomized, placebo-controlled trials examining the use of ...

Amneal has received Food and Drug Administration approval for its lidocaine patch 5%. The product is a generic of Lidoderm Patch 5%. “We are pleased to announce the approval for the Lidocaine Patch, 5 ...

A preclinical study commissioned by Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm ...

Scilex Holding Company announced the publication of a study in Pain Medicine News revealing that patients treated with ZTlido® (lidocaine topical system 1.8%) showed a greater reduction in opioid use ...